SGLT2 Inhibitor Clinical Resource Guide
JARDIANCE, INVOKANA, and FARXIGA belong to the class of drugs known as sodium glucose co-transporter 2 inhibitors (SGLT2-i) and the class of drugs were initially approved to treat type 2 diabetes. They have since gained FDA approval to treat heart failure and chronic kidney disease. This guidance document will educate on the role of SGLT2-I in the setting of palliative care and hospice, provide patient-specific clinical considerations and serve as a guide to navigate the appropriateness of deprescribing medications with this pharmacologic class...Download Full PDF
